Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Cash from Operations (2022 - 2025)

TriSalus Life Sciences' Cash from Operations history spans 4 years, with the latest figure at 2484000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 56.47% year-over-year to 2484000.0; the TTM value through Dec 2025 reached 18012000.0, up 55.9%, while the annual FY2025 figure was 18012000.0, 55.9% up from the prior year.
  • Cash from Operations reached 2484000.0 in Q4 2025 per TLSIW's latest filing, up from 3709000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 425954.0 in Q1 2022 to a low of 22880298.0 in Q3 2022.
  • Average Cash from Operations over 4 years is 8859125.0, with a median of 8743500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 2365.76% in 2023, then soared 65.81% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 8310000.0 in 2022, then fell by 10.43% to 9177000.0 in 2023, then soared by 37.81% to 5707000.0 in 2024, then soared by 56.47% to 2484000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Cash from Operations are 2484000.0 (Q4 2025), 3709000.0 (Q3 2025), and 7320000.0 (Q2 2025).